This Article Full Text Full Text (PDF) Other Versions of this Article: CVI.00319-07v1 15/2/260    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by van Ginkel, F. W. Articles by Tomich, J. M. Search for Related Content PubMed PubMed Citation Articles by van Ginkel, F. W. Articles by Tomich, J. M.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2008, p. 260-266, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00319-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Immunity to a Self-Derived, Channel-Forming Peptide in the Respiratory Tract

Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, Alabama 36849,¹ Department of Biochemistry,² Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas 66506³

Received 1 August 2007/ Returned for modification 14 November 2007/ Accepted 6 December 2007

The channel-forming peptide NC-1130 was generated based on the amino acid sequence of the M2 segment of the spinal cord -subunit of the glycine receptor and has been proposed as a therapeutic agent for anion channelopathies such as cystic fibrosis. Lysine adduction and amino acid substitutions at positions T19R and S22W of the peptide improved its performance as an ion channel. However, these modifications generated an altered self, potentially making this NC-1130 peptide immunogenic, which could preclude the repeated use of NC-1130 as a therapeutic agent. To measure the ability of NC-1130 to induce an immune response, it was administered nasally with or without cholera toxin (CT). The NC-1130 peptide, when given alone without adjuvant, induced very little peptide-specific immunity based on analyses of peptide-specific antibodies by enzyme-linked immunosorbent assay and enzyme-linked immunospot assay, induction of cytokine production, and delayed-type hypersensitivity (DTH) responses. The administration of NC-1130 with the mucosal adjuvant CT induced peptide-specific immunoglobulin G (IgG) antibodies and DTH responses and a Th2-dominant cytokine response. The coadministration of the strong mucosal adjuvant CT induced a systemic NC-1130-specific IgG response but not a mucosal peptide-specific antibody response. The lack of peptide-specific immunity and specifically mucosal immunity should allow repeated NC-1130 peptide applications to epithelial surfaces to correct anion channelopathies.

Published ahead of print on 19 December 2007.